1. Evolocumab successfully reduced low density lipoprotein (LDL) cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia.
2. Non- high density lipoprotein and apolipoprotein B levels were also improved in the evolocumab group.
Evidence Rating Level: 1 (Excellent)
Study Rundown: In the adult patient population with hyperlipidemia, human monoclonal antibodies that inhibitor...